correct me if wrong,but I believe they said that they have introduced this possibility,in the past months. In my view success now depends on pharma QC development and launch. The clinical market is too slow to take up the technology . Anyway the current MC of 2? million makes this a compelling investment..i expect to exit with a profit at MC 18 million,Shares 0.015. The main risk is Astra zenica not proceeding.
- Forums
- ASX - By Stock
- LBT
- Ann: Renounceable Rights Issue Results
Ann: Renounceable Rights Issue Results, page-7
Featured News
Add LBT (ASX) to my watchlist
|
|||||
Last
1.8¢ |
Change
0.002(12.5%) |
Mkt cap ! $24.24M |
Open | High | Low | Value | Volume |
1.7¢ | 1.8¢ | 1.7¢ | $2.279K | 130.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 828824 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 575392 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 828824 | 0.017 |
4 | 1162499 | 0.016 |
4 | 1551196 | 0.015 |
4 | 258714 | 0.014 |
1 | 50000 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 575392 | 3 |
0.019 | 53733 | 2 |
0.020 | 660000 | 3 |
0.021 | 524242 | 3 |
0.022 | 483292 | 4 |
Last trade - 11.52am 20/06/2024 (20 minute delay) ? |
Featured News
LBT (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Chairman
Nick Poll
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online